key: cord-0943890-xj774cx5
authors: Petersen, Steffen E.; Friedrich, Matthias G.; Leiner, Tim; Elias, Matthew D.; Ferreira, Vanessa M.; Fenski, Maximilian; Flamm, Scott D.; Fogel, Mark; Garg, Ria; Halushka, Marc K.; Hays, Allison G.; Kawel-Boehm, Nadine; Kramer, Christopher M.; Nagel, Eike; Ntusi, Ntobeko A.B.; Ostenfeld, Ellen; Pennell, Dudley J.; Raisi-Estabragh, Zahra; Reeder, Scott B.; Rochitte, Carlos E.; Starekova, Jitka; Suchá, Dominika; Tao, Qian; Schulz-Menger, Jeanette; Bluemke, David A.
title: Cardiovascular Magnetic Resonance for Patients With COVID-19
date: 2021-10-13
journal: JACC Cardiovasc Imaging
DOI: 10.1016/j.jcmg.2021.08.021
sha: a9c94e9ec89daddc0b0ed4e51e284b3849d5e552
doc_id: 943890
cord_uid: xj774cx5

COVID-19 is associated with myocardial injury caused by ischemia, inflammation, or myocarditis. Cardiovascular magnetic resonance (CMR) is the noninvasive reference standard for cardiac function, structure, and tissue composition. CMR is a potentially valuable diagnostic tool in patients with COVID-19 presenting with myocardial injury and evidence of cardiac dysfunction. Although COVID-19–related myocarditis is likely infrequent, COVID-19–related cardiovascular histopathology findings have been reported in up to 48% of patients, raising the concern for long-term myocardial injury. Studies to date report CMR abnormalities in 26% to 60% of hospitalized patients who have recovered from COVID-19, including functional impairment, myocardial tissue abnormalities, late gadolinium enhancement, or pericardial abnormalities. In athletes post–COVID-19, CMR has detected myocarditis-like abnormalities. In children, multisystem inflammatory syndrome may occur 2 to 6 weeks after infection; associated myocarditis and coronary artery aneurysms are evaluable by CMR. At this time, our understanding of COVID-19–related cardiovascular involvement is incomplete, and multiple studies are planned to evaluate patients with COVID-19 using CMR. In this review, we summarize existing studies of CMR for patients with COVID-19 and present ongoing research. We also provide recommendations for clinical use of CMR for patients with acute symptoms or who are recovering from COVID-19.

A s of July 2021, the worldwide number of confirmed COVID-19 cases has reached more than 180 million, with almost 4 million related deaths (1) .

SARS-CoV-2, which causes COVID-19, preferentially infects epithelial cells of the respiratory tract via the angiotensinconverting enzyme 2 (ACE2) receptor (2) .

However, both the heart and myocardial vessels are also potential targets of SARS- [8] ) as well as nonischemic injury (ie, myocarditis) (9) (10) (11) , stress cardiomyopathy (12), acute heart failure (13) , and secondary cardiac injury caused by sepsis and critical illness (14) . Mechanisms of myocardial injury may be direct (viral infection, thought to be less common) or indirect via systemic inflammatory response. Activation of a proinflammatory response secondary to an immune response to SARS-CoV-2 results in cytokine release and a prothrombotic state (15, 16) . Giustino et al (17) reported 305 patients hospitalized with COVID-19 from 7 hospitals in Milan and New York. Myocardial injury (defined as cardiac troponin [cTn] elevation above the 99th percentile upper reference limit [18] ) at any time during admission was common-present in 62% of patients. Elevated cTn was associated with older age, pre-existing cardiovascular disease, COVID-19 severity, and clinical deterioration (15, 19) . In other studies, patients with elevated cTn were at higher risk for adverse events during hospitalization, including a higher death rate, acute respiratory distress syndrome, and malignant arrhythmias (19) (20) (21) .

Myocardial injury in patients with COVID-19 can be detected by cardiac imaging. Giustino rose to 32% in those with myocardial injury and echocardiographic abnormalities (17) . These findings were supported by Rath et al (22) , who showed a significantly higher mortality in patients with impaired LV ejection fraction, impaired RV function, and tricuspid regurgitation. In 100 consecutive individuals hospitalized with COVID-19, Szekely et al (23) Values for age are mean AE SD or median (interquartile range). b Elevated hsTnT indicates a level of >99th percentile upper reference limit; hsTnT, N-terminal pro-b-type natriuretic peptide.

ACS ¼ acute coronary syndrome; BMI ¼ body mass index; CAD ¼ coronary artery disease; CMR ¼ cardiovascular magnetic resonance; LGE-positive patients had significantly decreased LV and RV peak global circumferential strain and poorer RV peak global longitudinal strain compared to non-LGE patients (P < 0.05), whereas no difference was found between the non-LGE patients and healthy control individuals None 45% (n ¼ 13) of patients had "myocarditis-like" LGE 7% (n ¼ 2) of patients had midwall LGE only 7% (n ¼ 2) of patients had ischemic LGE For 31% (n ¼ 9) of patients, elevated hsTnT was attributed to an ischemic cause. Of these, 7 had inducible ischemia, 1 had prior myocardial infarction, and 1 had both inducible ischemia and a prior infarction by CMR.

In patients with "myocarditis-like LGE," there was no significant difference in peak myocardial T 2 compared to the rest of the cohort 

As a result of the close congregation and contact of players during practice and competition, there is an increased risk of COVID-19 infections among athletes.

Exercise initiated too early after viral infection or in occult myocarditis may have serious consequences (47, 48) . Indeed, non-COVID-19 myocarditis accounts for 4% to 8% of sudden cardiac deaths in athletes (49, 50) or may lead to long-term complications such as myocardial scarring, arrhythmias, and myocardial dysfunction. Values are n, %, mean AE SD, or n/N (%). All were retrospective studies except for Rajpal et al (52) and Vago et al (56) , which were prospective studies. a Myocarditis diagnosis based on CMR findings as per updated Lake Louise criteria (58) . b Segment location given according to 17-segment American Heart Association model of the LV. c Number who underwent CMR. d CMR criteria for myocarditis not specified. e Number who underwent primary screening CMR.

GLS ¼ global longitudinal strain; not applicable ¼ not applicable or not given; TTE ¼ transthoracic echocardiography; other abbreviations as in Table 2 . Table 1 ).

Multisystem inflammatory syndrome in children LGE (72) (73) (74) (75) (76) (77) . However, in a few studies evaluating CMRs closer to 2 to 3 months after discharge, there were frequently no abnormalities (78, 79) .

PLANNED AND ONGOING STUDIES

The use of CMR in the context of COVID-19 is driven by the accuracy and reproducibility of the method and its unique role in myocardial tissue characterization (Central Illustration). Supplemental Table 2 

The appropriate use of CMR and its role in the treat- Table 2 ). To address the current gap in knowledge, a diverse group of investigators from 9 countries (principally cardiologists and radiologists with extensive experience in CMR) were assembled to Longer-term studies are necessary to determine the clinical importance of CMR metrics and their association with incident health outcomes. Comparison to control groups (matched for cardiovascular risk factors and severity-matched non-COVID illness when feasible) will ultimately help determine the relationship of CMR findings to long-term patient outcomes.

Dr Petersen provides consultancy to and is a shareholder of Circle Twitter: @RadiologyEditor.

Given the high rate of acute cardiovascular abnormalities in COVID-19 reported in clinical and pathologic series, concern exists for long-term myocardial injury in convalescent patients.

We review existing studies of CMR in COVID-19 and discuss the use of CMR for the acute and convalescent patients, including athletes.

Existing evidence is limited by small cohort sizes; absence of longitudinal follow-up; and, in some cases, lack of appropriate controls.

Evaluation of emerging evidence from ongoing and planned international studies will be essential for more robust evidence-based clinical decision making.

World Health Organization. Coronavirus disease Q28 (COVID-19) dashboard

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Multimodality imaging in evaluation of cardiovascular complications in patients with COVID-19: JACC scientific expert panel

Screening of potential cardiac involvement in competitive athletes recovering from COVID-19: an expert consensus statement

ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19

Education/COVID-19-and-Cardiology/ ESC-COVID-19-Guidance 7. Society for Cardiovascular Magnetic Resonance

STsegment elevation in patients with Covid-19-A case series

Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)

Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes

Suspected myocardial injury in patients with COVID-19: evidence from front-line clinical observation in Wuhan, China

Haemodynamic and therapeutic considerations

Heart failure with preserved ejection fraction in coronavirus disease 2019 patients: the promising role of diuretic therapy in critically ill patients

Myocardial injury in severe COVID-19 is similar to pneumonias of other origin: results from a multicentre study

Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Characterization of myocardial injury in patients with COVID-19

Fourth universal definition of myocardial infarction

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection

Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection

Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study

Global evaluation of echocardiography in patients with COVID-19

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Cardiopulmonary recovery after COVID-19-an observational prospective multi-center trial

Myocytespecific upregulation of ACE2 in cardiovascular disease: implications for SARS-CoV-2-mediated myocarditis

Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study

Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. Cardiovasc Pathol

Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases

COVID-19-associated nonocclusive fibrin microthrombi in the heart

Microthrombi as a major cause of cardiac injury in COVID-19: a pathologic study

cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations

Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis the MyoRacer-Trial

Society for Cardiovascular Magnetic Resonance (SCMR) recommended CMR protocols for scanning patients with active or convalescent phase COVID-19 infection

Einstein (São Paulo)

Patients recovered from COVID-19 show ongoing subclinical myocarditis as revealed by cardiac magnetic resonance imaging

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)

Prospective case-control study of cardiovascular abnormalities 6 months following mild COVID-19 in healthcare workers

Elevated extracellular volume fraction and reduced global longitudinal strains in patients recovered from COVID-19 without clinical cardiac findings

Cardiac involvement in COVID-19 patients: mid-term follow up by cardiovascular magnetic resonance

COVID-19 myocardial injury in survivors

Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance

Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging

Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge

Adverse cardiovascular magnetic resonance phenotypes are associated with greater likelihood of incident coronavirus disease 2019: findings from the UK Biobank

Myocarditis in athletes: a clinical perspective

Coxsackievirus B3 myocarditis in C3H/ HeJ mice: description of an inbred model and the effect of exercise on virulence

Sports-related sudden death in the general population

Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities

Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: a scientific statement from the American Heart Association and American College of Cardiology

Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection

Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection

High prevalence of pericardial involvement in college student athletes recovering from COVID-19

Cardiac involvement in consecutive elite athletes recovered from Covid-19: a magnetic resonance study

Cardiac magnetic resonance findings in patients recovered from COVID-19: initial experiences in elite athletes

COVID-19 myocardial pathology evaluation in athletes with cardiac magnetic resonance

Evaluation for myocarditis in competitive student athletes recovering from coronavirus disease 2019 with cardiac magnetic resonance imaging

Prevalence of inflammatory heart disease among professional athletes with prior COVID-19 infection who received systematic return-to-play cardiac screening

Cardiovascular evaluation after COVID-19 in 137 collegiate athletes: results of an algorithmguided screening

SARS-CoV-2 cardiac involvement in young competitive athletes

Prevalence and pattern of cardiovascular magnetic resonance late gadolinium enhancement in highly trained endurance athletes

Paediatric-multisystem-%20inflammatory%20 syndrome-20200501.pdf 63. Centers for Disease Control and Prevention Health Alert Network. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19)

COVID-19-associated multisystem inflammatory syndrome in children-United States

Multisystem inflammatory syndrome in U.S. children and adolescents

Management of multisystem inflammatory syndrome in children associated with COVID-19: a survey from the International Kawasaki Disease Registry

Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2

Multisystem inflammatory syndrome in children in New York State

COVID-19 and multisystem inflammatory syndrome in children and adolescents

Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19

Cardiac MRI in children with multisystem inflammatory syndrome associated with COVID-19

Cardiovascular magnetic resonance in myocarditis related to multisystem inflammatory syndrome in children associated with COVID-19

Multimodality cardiac evaluation in children and young adults with multisystem inflammation associated with COVID-19

Imaging findings of multisystem inflammatory syndrome in children associated with COVID-19

Early echocardiographic and cardiac MRI findings in multisystem inflammatory syndrome in children

Short-term sequelae of multisystem inflammatory syndrome in children assessed by CMR

Cardiovascular magnetic resonance imaging in children after recovery from symptomatic COVID-19 or MIS-C: a prospective study

Cardiac magnetic resonance followup of children after pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV -2 with initial cardiac involvement

World Health Organization. COVID-19 clinical management: living guidance

National Institutes of Health. COVID-19 treatment guidelines: clinical spectrum of SAR-SCoV-2 infection

Children's Hospital of Philadelphia. Multisystem inflammatory syndrome (MIS-C) clinical pathway-emergency, ICU and inpatient